Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13462578 | 1.00 | KDM1A (0.43) | KDM1AHRH3HRH2HRH1MEN1 | |
| SCHEMBL12155274 | 1.00 | KDM1A (0.43) | KDM1AHRH3HRH2HRH1MEN1 | |
| SCHEMBL13472608 | 0.88 | HRH3 (0.47) | KDM1AHRH3HRH2HRH1DRD2 | |
| SCHEMBL16511589 | 0.88 | HRH3 (0.47) | KDM1AHRH3HRH2HRH1DRD2 | |
| SCHEMBL10223659 | 0.87 | DRD2 (0.44) | MEN1RAB9AKMT2ADRD2 | |
| SCHEMBL23219727 | 0.85 | GNAO1 (0.51) | HRH3HRH2HRH1 | |
| SCHEMBL24316250 | 0.84 | NOS3 (0.38) | HRH3MEN1RAB9AKMT2ADRD2 | |
| SCHEMBL734698 | 0.83 | HRH3 (0.41) | KDM1AHRH3HRH2HRH1 | |
| SCHEMBL684126 | 0.83 | HRH3 (0.41) | KDM1AHRH3HRH2HRH1 | |
| SCHEMBL8434577 | 0.83 | HRH3 (0.41) | KDM1AHRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015089481-A2 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20120115819-A1 | Pentacycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-10 | — | — | US | disclosed |
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | disclosed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TSLP, IL5, IL17A | KDM1A 3577/4885HRH3 3903/4885HRH2 2539/4885 |
| US-20080293687-A1 | Benzamide Compounds | HDAC1, HDAC11, HDAC2 | KDM1A 57/4885HRH3 59/4885HRH2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.